title: EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
abstract: To test the recently developed EUTOS score in predicting optimal response to imatinib and the long-term outcome, 265 patients with early chronic phase chronic myeloid leukaemia treated with standard dose imatinib were analysed. Achievement of optimal response endpoints were higher in low-risk patients, though the difference was not statistically significant: PCyR at 6th month 86% vs 67% (p=0.06), CCyR at 12th month 80% vs 63% (p=0.09), MMR at 18th month 61% vs 36% (p=0.11). However, EUTOS score was predictive for the long-term response. With a median follow-up of 61 months, 53% high-risk patients experienced imatinib failure, compared to 23% in the low-risk group (p=0.013). Among high-risk patients, 4/17 (23%) progressed to accelerated/blastic phase or died, compared to 11/248 (5%) low-risk patients, with 5-year progression-free survival rates of 84±10% and 96±1%, respectively (p=0.04). Our data confirm that EUTOS score envisions the long-term outcome of imatinib therapy.
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliero - Universitaria di Udine, Italy. Electronic address: mario.tiribelli@uniud.it.
authors.forename: Mario
authors.initials: M
authors.lastname: Tiribelli
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bonifacio
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Calistri
authors.forename: Gianni
authors.initials: G
authors.lastname: Binotto
authors.forename: Elena
authors.initials: E
authors.lastname: Maino
authors.forename: Luciana
authors.initials: L
authors.lastname: Marin
authors.forename: Emanuele
authors.initials: E
authors.lastname: Guardalben
authors.forename: Antonio
authors.initials: A
authors.lastname: Branca
authors.forename: Filippo
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: Gianpietro
authors.initials: G
authors.lastname: Semenzato
authors.forename: Rosaria
authors.initials: R
authors.lastname: Sancetta
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D019937:Diagnostic Techniques and Procedures; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D055815:Young Adult
chemical_list: D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: Chronic myeloid leukaemia; EUTOS score; Imatinib; Prognosis